secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immix Biopharma, Inc. (IMMX)
CIK:        0001873835
Form:       8-K
Filed at:   2023-07-14T23:59:59+00:00
Accession:  0001493152-23-024626
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immix Biopharma enters ATM equity offering agreement with ThinkEquity LLC
-------------------------------------------------------------------------

- ATM Sales Agreement with ThinkEquity LLC allows at-the-market sales of common stock, subject to $75M public float limitation.
- Commission rate of 3.75% of gross proceeds; company also reimburses legal fees up to $50,000 and quarterly fees.
- Sales may occur on Nasdaq Capital Market or other trading markets at prevailing prices; agreement terminable on 10 days' notice.
- Prospectus supplement filed July 14, 2023 under effective shelf registration statement (333-269100).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873835/000149315223024626/0001493152-23-024626-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873835/000149315223024626/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-024626

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer